Research Overview
Across the studies reviewed here, “DLPA” research is dominated by clinical and behavioral studies where DLPA refers to daily life physical activity, most often quantified objectively using accelerometry or pedometers. The most studied areas are chronic respiratory and cardiopulmonary diseases—particularly COPD, pulmonary arterial hypertension (PAH), and asthma—where DLPA is evaluated as (i) an outcome in randomized or controlled interventions (e.g., selexipag in PAH; elastic tape in COPD), and (ii) a correlate of patient-reported constructs such as illness perceptions, dyspnea, health-related quality of life (HRQoL), and self-efficacy. A smaller, mechanistic/basic-science thread uses “DLPA” to denote dilauroyl phosphatidic acid in membrane/enzymology contexts (e.g., interactions with perfluorodecanoic acid; substrate specificity of plant secretory phospholipase A2), which is conceptually distinct from the clinical DLPA literature and does not directly inform physical-activity measurement.
The strongest evidence supported by these studies is methodological and descriptive: actigraphy/accelerometry is feasible in relevant patient populations, with high device-wear compliance demonstrated in PAH, and it can characterize both central tendency and variability of activity metrics. Substantively, the intervention studies summarized here provide consistent evidence that short-term or add-on interventions may improve symptoms and patient-reported outcomes without necessarily producing measurable increases in objectively assessed DLPA. In PAH, selexipag vs placebo showed small, highly variable, and statistically non-significant changes in nonsedentary time, moderate-to-vigorous activity, and steps over 24 weeks in a low-risk, background-therapy population. In COPD, elastic tape improved dyspnea and HRQoL (including clinically meaningful changes) but did not change DLPA in between-group comparisons. Observationally, DLPA did not differ between COPD illness-perception clusters despite marked differences in dyspnea, HRQoL, and self-efficacy, and moderate-to-severe asthmatic women had similar step counts to controls, with DLPA correlating modestly with the activity-limitation domain of asthma-specific QoL.
Key gaps highlighted by this set of studies include the need for larger and/or better-targeted trials to detect clinically meaningful DLPA changes, given the high variability of actigraphy endpoints and the possibility of ceiling effects in stable or low-risk cohorts. More research is needed to clarify when symptom/HRQoL improvements translate into real-world activity gains, to identify determinants and mediators of DLPA (e.g., behavioral, psychosocial, educational, and environmental factors), and to standardize DLPA endpoints (definitions of sedentary/nonsedentary time, MVPA thresholds, wear-time rules, and analytic approaches) to improve comparability across studies. Additionally, the dual use of “DLPA” (physical activity vs dilauroyl phosphatidic acid) underscores a nomenclature issue: future syntheses should explicitly disambiguate terms to avoid conflating clinical activity research with lipid/membrane biophysics and enzymology, which require separate evidence frameworks.
1. What conditions has DLPA been studied for?
The studies reviewed here use the acronym “DLPA” in multiple, unrelated ways. Only one abstract clearly refers to a supplement-like compound (DL-phenylalanine, written as DL-PA), while several others use “DLPA” to mean “daily life physical activity,” and others use DLPA as a lipid (dilauroyl phosphatidic acid) or as a technical acronym in engineering/computer science.
DLPA as “daily life physical activity” (DLPA): studied as an outcome measure in:
Pulmonary arterial hypertension (PAH) in a randomized trial of selexipag vs placebo (TRACE).
Chronic obstructive pulmonary disease (COPD): illness perception clusters vs DLPA (cross-sectional); and elastic tape intervention vs control (RCT).
Asthma: DLPA compared between moderate-to-severe asthmatic women and healthy controls (observational).
DLPA as a lipid (dilauroyl phosphatidic acid): studied in membrane/biophysics and enzymology contexts:
Interaction of perfluorodecanoic acid (PFD) with lipid membrane models including DLPA (Langmuir monolayers/vesicles).
Substrate specificity of soybean secretory phospholipase A2 enzymes using DLPA among other phospholipids.
DL-PA (DL-phenylalanine): appears in an electrochemical sensor paper as a polymerized modifier on an electrode for detecting caffeic acid and riboflavin (an analytical chemistry application, not a clinical condition).
DLPA as a technical acronym: appears as “distributed Laplace mechanism” for differential privacy and as “diffraction line profile analysis” in materials science—neither is a health condition.
2. Does it work in treating those conditions? Summarize the evidence.
As a treatment, the studies reviewed here do not show DLPA (as a supplement) treating any medical condition. The clinical studies that mention “DLPA” are referring to daily life physical activity as an outcome, not a therapy.
PAH (TRACE trial): DLPA (daily life physical activity) was measured by actigraphy to see whether selexipag changes activity. Changes were “small and highly variable,” with no statistically significant differences between selexipag and placebo for nonsedentary physical activity, moderate-to-vigorous physical activity, or steps (confidence intervals crossed zero).
COPD (illness perception clusters): Distressed vs coping clusters differed in symptoms, HRQoL, self-efficacy, etc., but DLPA levels did not differ between clusters.
COPD (elastic tape RCT): Elastic tape did not modify DLPA in between-group comparisons, though the control group’s steps declined while the taped group largely maintained steps. The intervention improved dyspnea and quality-of-life measures (see Q3), but this is not DLPA as a supplement.
Asthma observational study: Moderate-to-severe asthmatic women had no difference in DLPA (steps/day) vs controls; DLPA correlated with the activity limitation domain of asthma quality of life.
DL-phenylalanine (DL-PA): The only DL-PA abstract is about an electrochemical sensor; it provides no evidence of clinical treatment efficacy for any condition.
Bottom line: Based on these studies, there is no clinical evidence presented that DLPA (as a supplement) treats PAH, COPD, asthma, or any other condition.
3. What health benefits does it have?
The studies reviewed here do not demonstrate direct health benefits of “DLPA” as a supplement. However, they do provide health-related findings in studies where DLPA means “daily life physical activity” (an outcome) or where other interventions affected symptoms/quality of life.
Elastic tape in COPD (not DLPA the supplement): despite no DLPA increase, the intervention group had:
Reduced dyspnea (improved Transition Dyspnea Index domains and mMRC; p<0.01).
Improved health status (CAT score improved by −4.4, reaching MCID; p<0.01).
Improved HRQoL (most CRQ domains improved, reaching MCID by Day 21).
Asthma: DLPA (steps/day) correlated with the activity limitation domain of asthma quality of life (r=0.43, p<0.01), suggesting that perceived limitations relate to objectively measured activity, but this is not a demonstrated “benefit” of DLPA itself.
PAH TRACE trial: the study primarily demonstrates feasibility of actigraphy and describes variability; it does not show a clear improvement in DLPA outcomes with selexipag vs placebo.
If your intent is specifically DL-phenylalanine (DLPA) as a dietary supplement, these studies do not provide evidence for benefits such as pain relief, mood effects, or other commonly marketed claims.
4. Does it have any downsides or side effects?
The studies reviewed here do not report adverse events or side effects attributable to “DLPA” as a supplement.
PAH TRACE trial: the study focuses on activity outcomes and compliance with accelerometer wear; it does not describe safety outcomes in the excerpt provided.
COPD elastic tape trial: the study does not report adverse effects of the tape intervention.
Membrane/biophysics and enzymology studies involving DLPA (lipid): these are mechanistic laboratory studies and do not translate into human side-effect profiles.
DL-phenylalanine (DL-PA) sensor paper: not a clinical exposure/supplementation study; no side effects discussed.
Limitation: Without clinical supplementation studies of DL-phenylalanine (DLPA) in these studies, no evidence-based conclusions about side effects (e.g., nausea, headache, blood pressure effects, interactions, or concerns in phenylketonuria) can be drawn from the provided text.
5. Is it beneficial or harmful for any genetic variations (pharmacogenomics)?
No pharmacogenomic or genotype-stratified findings are reported in the studies reviewed here for any meaning of “DLPA,” including DL-phenylalanine (DLPA) as a compound.
No genetic variants (e.g., metabolic enzyme polymorphisms, transporter variants, receptor variants) are discussed in relation to DLPA/DL-PA.
No subgroup analyses by genotype are described for PAH, COPD, or asthma studies (which use DLPA as an activity metric).
Conclusion: Based on these studies alone, there is no evidence that DLPA is beneficial or harmful for specific genetic variations.
References
-
Assessing Daily Life Physical Activity by Actigraphy in Pulmonary Arterial Hypertension: Insights From the Randomized Controlled Study With Selexipag (TRACE).
Luke S Howard, Stephan Rosenkranz, Robert P Frantz, Anna R Hemnes, Thomas Pfister, Shu-Fang Hsu Schmitz, Hall Skåra, Marc Humbert, Ioana R Preston (2023) - Chest -
Identifying COPD patients at risk for worse symptoms, HRQoL, and self-efficacy: A cluster analysis.
Aline C Lopes, Rafaella F Xavier, Ana Carolina Ac Pereira, Rafael Stelmach, Frederico LA Fernandes, Samantha L Harrison, Celso Rf Carvalho (2019) - Chronic illness -
Elastic tape reduces dyspnea and improves health status in the short term in nonobese COPD males: A randomized controlled trial.
Eloise Arruda Dos Santos, Thiago Fernandes Pinto, Rafaella Fagundes Xavier, Rafael Stelmach, Regina Maria Carvalho-Pinto, Celso Ricardo Fernandes de Carvalho (2024) - Respiratory medicine -
Destabilizing effect of perfluorodecanoic acid on simple membrane models.
Benjamin Viada, Candelaria I Cámara, Lidia M Yudi (2019) - Soft matter -
Objectively measured daily-life physical activity of moderate-to-severe Brazilian asthmatic women in comparison to healthy controls: A cross-sectional study.
Cristina Martins Coelho, Larissa Almeida Campos, Fabiana Oliveira Pereira, Ranieri Monteiro Cardoso, Lucas Mendes Nascimento, Jessica Blanc Leite Oliveira, Lucas Ricardo Andrade, Erich Vidal Carvalho, Maycon Moura Reboredo, Bruno Valle Pinheiro (2018) - The Journal of asthma : official journal of the Association for the Care of Asthma -
Kinetic characterization, optimum conditions for catalysis and substrate preference of secretory phospholipase A2 from Glycine max in model membrane systems.
María Elisa Mariani, Ricardo Román Madoery, Gerardo Daniel Fidelio (2015) - Biochimie -
A Comprehensive Comparison of Multiparty Secure Additions with Differential Privacy.
Slawomir Goryczka, Li Xiong (2017) - IEEE transactions on dependable and secure computing -
Diagnostic value of 3D volume measurement of central pulmonary artery based on CTPA images in the pulmonary hypertension.
Wanwan Zhao, Jialing Guo, Ningli Dong, Huanhuan Hei, Xiaoyi Duan, Cong Shen (2023) - BMC medical imaging -
Data-driven analysis of neutron diffraction line profiles: application to plastically deformed Ta.
Aaron E Tallman, Reeju Pokharel, Darshan Bamney, Douglas E Spearot, Bjorn Clausen, Ricardo A Lebensohn, Donald Brown, Laurent Capolungo (2022) - Scientific reports -
Electrochemical polymerized DL-phenylalanine modified carbon nanotube sensor for the selective and sensitive determination of caffeic acid with riboflavin.
Kanthappa B, J G Manjunatha, Sameh Mohamed Osman, Narges Ataollahi (2024) - Scientific reports
This article summarizes published research for educational purposes. It is not medical advice. Talk to your doctor before starting, stopping, or changing any supplement or medication.
Upload Whole Genome Sequencing (WGS) raw DNA data today!
Or upload raw DNA data to get started with your free analysis!